Literature DB >> 25062396

Utility of Framingham risk score in urban emergency department patients with asymptomatic hypertension.

Aaron M Brody1, John M Flack, Brian A Ference, Phillip D Levy.   

Abstract

Hypertension (HTN) is the primary population-attributable risk for the development of heart failure (HF); a disease with devastating consequences particularly in urban centers where morbidity and mortality are more pronounced. The Framingham Risk Profile (FRP) is widely used to quantify risk for cardiovascular disease (CVD), but its applicability in an urban population who utilize the emergency department (ED) for primary care is unknown. The objective of this study is to evaluate FRP scores in ED patients with asymptomatic HTN and subclinical hypertensive heart disease (SHHD). This is a substudy of a prospective randomized clinical trial designed to evaluate optimal blood pressure (BP) targets. Eligible patients were screened with echocardiography for the presence of SHHD and FRP scores were calculated. One hundred forty-nine patients enrolled in the study, 133 (89.2%) of whom had detectable SHHD. Mean [SD] calculated FRP scores were statistically similar for patients with SHHD versus those without (general CVD: 20.2 [8.5] vs. 15.6 [8.7]; P = 0.13 and HF calibrated: 2.4 [1.0] vs. 1.8 [1.0]; P = 0.12) corresponding to a calculated risk of 15%-30% for subsequent development of CVD. The HF-specific risk score for patients with SHHD was 2.4, which equates to a 2.5% risk of HF development in 10 years. The FRP correctly identified those with SHHD as high-risk for general CVD but appeared to underestimate the likelihood of HF. Recalibration of the HF adjustment factor and inclusion of additional data elements such as echocardiography is needed to enhance applicability of the FRP in this setting.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25062396      PMCID: PMC4113016          DOI: 10.1097/HPC.0000000000000016

Source DB:  PubMed          Journal:  Crit Pathw Cardiol        ISSN: 1535-2811


  31 in total

Review 1.  Heart failure in African Americans: a cardiovascular engima.

Authors:  C W Yancy
Journal:  J Card Fail       Date:  2000-09       Impact factor: 5.712

2.  Validation of the Framingham coronary heart disease prediction scores: results of a multiple ethnic groups investigation.

Authors:  R B D'Agostino; S Grundy; L M Sullivan; P Wilson
Journal:  JAMA       Date:  2001-07-11       Impact factor: 56.272

3.  Heart disease and stroke statistics--2014 update: a report from the American Heart Association.

Authors:  Alan S Go; Dariush Mozaffarian; Véronique L Roger; Emelia J Benjamin; Jarett D Berry; Michael J Blaha; Shifan Dai; Earl S Ford; Caroline S Fox; Sheila Franco; Heather J Fullerton; Cathleen Gillespie; Susan M Hailpern; John A Heit; Virginia J Howard; Mark D Huffman; Suzanne E Judd; Brett M Kissela; Steven J Kittner; Daniel T Lackland; Judith H Lichtman; Lynda D Lisabeth; Rachel H Mackey; David J Magid; Gregory M Marcus; Ariane Marelli; David B Matchar; Darren K McGuire; Emile R Mohler; Claudia S Moy; Michael E Mussolino; Robert W Neumar; Graham Nichol; Dilip K Pandey; Nina P Paynter; Matthew J Reeves; Paul D Sorlie; Joel Stein; Amytis Towfighi; Tanya N Turan; Salim S Virani; Nathan D Wong; Daniel Woo; Melanie B Turner
Journal:  Circulation       Date:  2013-12-18       Impact factor: 29.690

4.  Long-term trends in the incidence of and survival with heart failure.

Authors:  Daniel Levy; Satish Kenchaiah; Martin G Larson; Emelia J Benjamin; Michelle J Kupka; Kalon K L Ho; Joanne M Murabito; Ramachandran S Vasan
Journal:  N Engl J Med       Date:  2002-10-31       Impact factor: 91.245

5.  Contribution of major diseases to disparities in mortality.

Authors:  Mitchell D Wong; Martin F Shapiro; W John Boscardin; Susan L Ettner
Journal:  N Engl J Med       Date:  2002-11-14       Impact factor: 91.245

6.  Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol.

Authors:  Björn Dahlöf; Richard B Devereux; Sverre E Kjeldsen; Stevo Julius; Gareth Beevers; Ulf de Faire; Frej Fyhrquist; Hans Ibsen; Krister Kristiansson; Ole Lederballe-Pedersen; Lars H Lindholm; Markku S Nieminen; Per Omvik; Suzanne Oparil; Hans Wedel
Journal:  Lancet       Date:  2002-03-23       Impact factor: 79.321

7.  M-mode echocardiographic predictors of six- to seven-year incidence of coronary heart disease, stroke, congestive heart failure, and mortality in an elderly cohort (the Cardiovascular Health Study).

Authors:  J M Gardin; R McClelland; D Kitzman; J A Lima; W Bommer; H S Klopfenstein; N D Wong; V E Smith; J Gottdiener
Journal:  Am J Cardiol       Date:  2001-05-01       Impact factor: 2.778

8.  Hypertrophy at ECG and its regression during treatment survey (HEART survey). Rationale, design and baseline characteristics of patients.

Authors:  Paolo Verdecchia; Peter Sleight; Fausto Avanzini; Giovanni de Simone; Sergio Pede; Francesco Perticone; Giuseppe Schillaci; Diego Vanuzzo; Fabio Angeli; Gian Paolo Reboldi; Aldo P Maggioni
Journal:  Ital Heart J       Date:  2003-07

9.  Increased left ventricular mass is a risk factor for the development of a depressed left ventricular ejection fraction within five years: the Cardiovascular Health Study.

Authors:  Mark H Drazner; J Eduardo Rame; Emily K Marino; John S Gottdiener; Dalane W Kitzman; Julius M Gardin; Teri A Manolio; Daniel L Dries; David S Siscovick
Journal:  J Am Coll Cardiol       Date:  2004-06-16       Impact factor: 24.094

10.  The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report.

Authors:  Aram V Chobanian; George L Bakris; Henry R Black; William C Cushman; Lee A Green; Joseph L Izzo; Daniel W Jones; Barry J Materson; Suzanne Oparil; Jackson T Wright; Edward J Roccella
Journal:  JAMA       Date:  2003-05-14       Impact factor: 56.272

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.